Screener
UroGen Pharma URGN Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from exercise of options into ordinary shares | 1,066 | 327 |
| Proceeds from issuance of long-term debt, net | 65,346 | — |
| Proceeds from pre-funded warrant issuance, net of issuance costs | — | 3 |
| Net cash provided by financing activities | 65,704 | 330 |
| Decrease in Cash and Cash Equivalents | (31,633) | (79,076) |
| Cash, Cash Equivalents and Restricted Cash at Beginning of Period | 112,095 | 173,062 |
| Cash, Cash Equivalents and Restricted Cash at End of Period | $80,462 | $93,986 |
| Supplemental Disclosures of Non-Cash Activities |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's financing cash flow?
- UroGen Pharma (URGN) reported financing cash flow of $500K in Q2 2026.
- How has UroGen Pharma's financing cash flow changed year-over-year?
- UroGen Pharma's financing cash flow increased by 68.9% year-over-year, from $296K to $500K.
- What is the long-term trend for UroGen Pharma's financing cash flow?
- Over 3 years (2022 to 2025), UroGen Pharma's financing cash flow has grown at a -25.7% compound annual growth rate (CAGR), from $97.21M to $39.92M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about UroGen Pharma's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude